Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$8M
- −44.6% YoY
- EPS (diluted)
- −$0.05
- +28.6% YoY
Source: XBRL data from the SELLAS Life Sciences Group, Inc. (SLS) Q1 2026 10-Q on SEC EDGAR. USD.
SELLAS Life Sciences Group, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $0 in both quarters; licensing revenue only from 3D Medicines Agreement
- Operating margin not meaningful; operating loss $9.3M vs $6.1M YoY
- R&D expense $5.1M vs $3.2M; manufacturing and clinical supply $1.3M vs $0.1M
- Cash and equivalents $107.1M; operating cash outflow $8.8M vs $9.1M YoY
- Warrant exercises generated $44.1M; cash expected sufficient for at least twelve months
Risk Factors
- No material changes stated; 2025 Annual Report risks carried forward
- No newly added risk factor identified in the provided section
- No operational, competitive, market, liquidity, debt, currency, or concentration risk details provided
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SELLAS Life Sciences Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.